[The evaluation of cefmetazole in clinical use. The study group of cefmetazole in clinical use].
To study the clinical effect of cefmetazole (CMZ), we treated with CMZ 1,926 patients with various infections involving the respiratory tract, gastrointestinal tract, liver and biliary tract, skin and soft tissue and others. The marked effect rate was 56.5%, and the effect rate 33.7%. The sensitivity test of CMZ was also performed in vitro. Staphylococcus aureus, streptococcus, staphylococcus epidermis, E. coli, S. typhi, B. salmonella, B. shigella, B. Klebsiella pneumoniae, B. proteus, etc. were sensitive to CMZ. Injecting CMZ can prevent the infection of operation. The study of the adverse reaction of CMZ showed, an adverse reaction rate of 4.2% (the gastrointestinal tract, allergy, kidney and nervous system). These results suggested that CMZ is an antibiotic of broad spectrum, high efficacy and low toxicity. It is effective in treating sensitive bacterial infection, unknown pathogenic infection and mixed bacterial infection, and preventing infection in surgery.
Si
C
C
First Teaching Hospital, Beijing Medical University.
Tian
G
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015311:Cefmetazole / Q000627:therapeutic use*; D002513:Cephamycins / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy
D002513:Cephamycins; D015311:Cefmetazole